FDA
-
-
-
-
-
-
-
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Ayala Pharmaceuticals Inc. (AYLA) Granted FDA Fast Track Designation for AL102
-
-
-
-
-
-
-
Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress
-
-
-
-
-
-
-
Ayala Pharmaceuticals Announces Data on AL101 in Adenoid Cystic Carcinoma (ACC) at 2022 ASCO Annual Meeting
-
-
-
-
-
-
-
Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Ayala Pharmaceuticals Announces Completion of Enrollment in Part A of RINGSIDE, a Pivotal Phase 2/3 Study of AL102 in Desmoid Tumors
-
-
-
-
-
-
-
Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

